7월 28일 · 실적분석
실적분석
NeoGenomics ($NEO) Q2 2026 Earnings Analysis — Revenue and EPS Both Beat, Full-Year Guidance Raised, Shares Up 5% in Extended Trading
NEO NeoGenomics 실적 요약NeoGenomics ($NEO) delivered Q2 2026 revenue of $201.7 million (up 11.2% year-over-year) and adjusted EPS of $0.05, beating consensus estimates on both lines (revenue ~$196.99 million, EPS $0.034). The company slightly raised its full-year revenue forecast to a midpoint of $804 million and guided full-year adjusted EBITDA to $57 million. The most notable highlight was the sharp improvement in operating loss margin, narrowing from -26.3% a year ago to -4.8%. In extended trading immediately after the release, shares traded around $14.08, up roughly 5%. The company has not yet turned profitable, but the simultaneous improvement in growth and profitability is the key takeaway.
Earnings Scorecard
▸ Revenue: $201.7 million (up 11.2% year-over-year, +2.2% vs. consensus of ~$196.99 million) ✅ Beat
▸ EPS: Adjusted $0.05 (approximately +49% vs. consensus of $0.03) ✅ Beat
▸ Guidance: Raised — full-year revenue midpoint $804 million (prior ~$800 million), full-year adjusted EBITDA $57 million, full-year adjusted EPS $0.19
▸ Stock Reaction: Approximately +5% in extended trading to $14.08 (immediately after the release)
The Positives
▸ Return to double-digit growth: Revenue of $201.7 million rose 11.2% year-over-year and topped consensus by 2.2%
▸ Improved profitability profile: Operating loss margin improved by 21.5 percentage points, from -26.3% to -4.8%
▸ Cash generation: Free cash flow margin rose to 12.4% from 7.7% a year ago
NeoGenomics specializes in cancer diagnostic testing. It operates two businesses side by side: a Clinical segment that provides genetic and molecular diagnostic tests to hospitals and oncologists, and a Pharma segment that supplies testing services to pharmaceutical companies for their drug-development clinical trials. The fact that revenue this quarter grew at a double-digit rate means both test volume and price per test held up, which is no easy feat in a diagnostics industry under pressure from insurance reimbursement rates.
The more meaningful change, however, is on the profit-and-loss line. Operating loss margin is a measure of how much a company loses on its core business for every $100 of revenue. A year ago, the company was losing $26.3 per $100; this quarter, that figure fell to $4.8. Costs grew much more slowly than revenue, which signals that the structural advantage of a diagnostics business — where per-unit cost falls as test volume rises — is actually starting to kick in.
On top of that, free cash flow margin (the cash a company actually keeps in hand after operating and investing activities) climbed to 12.4%. That means a company still in accounting-loss territory is generating cash, which reduces the pressure to borrow externally or raise capital by issuing new shares.
The Drawbacks
▸ Still operating at a loss: Although improved, operating loss margin of -4.8% means the core business has not yet turned profitable
▸ Thin earnings profile: Adjusted EPS of $0.05 and full-year guidance of $0.19 leave earnings small relative to market cap
▸ Growth expectations: The full-year revenue raise was a modest adjustment, with the prior range sitting in the $400 million range — wait, the raise itself was only on the order of $4 million, not $400 million
The first point to flag is that this company is still not profitable. The $0.05 adjusted EPS is a figure calculated after excluding one-time items and other adjustments, and on a strict GAAP basis the bottom line is still in the red. Because adjusted numbers and GAAP numbers use different standards, beginner investors are better off keeping in mind that the company is "barely in the black on an adjusted basis."
The magnitude of the full-year guidance raise also deserves a sober look. The midpoint moved from $800 million to $804 million. Given that the company delivered roughly $4 million more than expected in Q2 alone, this is essentially the H1 beat being rolled into the full-year figure rather than management meaningfully raising its bar for the second half. One interpretation is that management is still viewing the H2 environment cautiously.
Finally, there is a risk common to the entire diagnostics industry. If U.S. public and private insurance reimbursement policies — that is, how much insurers pay per test — change, both revenue and margins can be shaken at the same time. The pharma-facing business is also sensitive to drug-development budget cuts, so both growth pillars are tied to external variables that the company does not directly control.
What Management Said
"This quarter's results demonstrate the consistent operational and financial performance our team has been working toward." — Tony Zook, CEO
Management's tone put its weight on steady execution rather than flashy leaps. In fact, the emphasis of the release was not on new initiatives or M&A, but on revenue growth and cost discipline playing out as planned. By raising full-year revenue guidance while also issuing guidance for adjusted EBITDA and adjusted EPS, the company signaled confidence not just in growth but in profitability targets as well.
The magnitude of the raise itself, however, was restrained. The market appears to have read this less as a "surprise leap" and more as a "company that keeps its promises," and the post-release move in extended trading is consistent with that interpretation.
Market Reaction and What to Watch Next
The reason the market pushed the stock up nearly 5% in extended trading is straightforward: both revenue and adjusted EPS beat expectations, and full-year guidance was raised on top of that. For a loss-making company reporting earnings, the scenario investors fear most is "growth was there, but losses were unchanged." This quarter, the sharp narrowing of operating loss margin took that concern off the table.
The move in free cash flow margin into double digits is particularly important for investor sentiment. When a company generates its own cash, the risk of diluting existing shareholders falls, and expectations grow that the timeline to profitability could be pulled forward. Conversely, the stock from here depends on whether this is a one-quarter pop or a trend.
▸ Whether the improvement in operating loss margin continues into Q3 and brings the core business closer to operating profitability
▸ Which of the two engines — clinical testing or pharma services — is driving growth, and what the quality of that growth looks like
▸ Whether the company actually delivers on the full-year targets of $804 million in revenue and $57 million in adjusted EBITDA in the second half
▸ The impact of U.S. insurance reimbursement policy changes on per-test pricing
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.
🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다